REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS FOR RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) AND MONOCLONAL ANTIBODIES (MAB) THERAPIES

被引：0
|
作者：
Feng, C. [1 ]
Murphy, L. [2 ]
Engel-Nitz, N. [2 ]
Nguyen, A. [2 ]
Patel, A. [1 ]
DuCharme, M. [2 ]
Fu, C. [1 ]
Shah, G. [3 ]
机构：
[1] Kite Pharma, Santa Monica, CA USA
[2] Optum, Eden Prairie, MN USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD178
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [31] Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma
    Hu, Bei
    Vaidya, Rakhee
    Ahmed, Ferdous
    Ehsan, Hamid
    Moyo, Tamara K.
    Jacobs, Ryan W.
    Pang, Yifan
    Park, Steven
    Wallander, Michelle L.
    Shroff, Vishal
    Boseman, Victoria
    Beam, Travis
    Elder, Jennifer
    Yountz, Melissa
    Jennings, Rebecca
    Howard, Dianna S.
    Avalos, Belinda
    Copelan, Edward A.
    Mesa, Ruben
    Ghosh, Nilanjan
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (11):
  • [32] COST EFFECTIVENESS OF THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE (2L) TREATMENT OF RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN SWITZERLAND
    Deger, K.
    Oniangue-Ndza, C.
    Elsada, A.
    Litkiewicz, M.
    Villalobos, Franco C.
    Sorensen, S.
    VALUE IN HEALTH, 2023, 26 (12) : S152 - S153
  • [33] Real-world treatment patterns among patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19-directed chimeric antigen receptor T-cell therapy (CAR T).
    Jalbert, Jessica J.
    Arnason, Jon E.
    Ge, Wenzhen
    Chen, Chieh-, I
    Ambati, Srikanth R.
    Wu, Ning
    Chaudhry, Aafia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
    Epperla, Narendranath
    Nastoupil, Loretta J.
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Gentile, Danielle
    Saverno, Kim
    BIOMARKER RESEARCH, 2025, 13 (01)
  • [35] Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
    Trando, Aaron
    Ter-Zakarian, Anna
    Yeung, Phillip
    Goodman, Aaron M.
    Hamdan, Ayad
    Hurley, Michael
    Jeong, Ah-Reum
    Tzachanis, Dimitrios
    CANCERS, 2023, 15 (18)
  • [36] DURABLE RESPONSES FOLLOWING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/ REFRACTORY LARGE B-CELL LYMPHOMA AFTER MULTIPLE LINES OF TREATMENT: THE HELLENIC REAL-WORLD EXPERIENCE
    Bampali, Vasiliki
    Dolgyras, Panagiotis
    Matheakakis, Angelos
    Alexandropoulos, Alexandros
    Tsonis, Ioannis
    Gavriilaki, Eleni
    Tzannou, Ifigeneia
    Batsis, Ioannis
    Tzenou, Tatiana
    Mallouri, Despina
    Bouzani, Maria
    Vardi, Anna
    Anagnostopoulos, Achilles
    Gigantes, Stavros
    Sotiropoulos, Damianos
    Karakasis, Dimitrios
    Baltadakis, Ioannis
    Sakellari, Ioanna
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 211 - 211
  • [37] Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
    Di, Mengyang
    Potnis, Kunal C.
    Long, Jessica B.
    Isufi, Iris
    Foss, Francine
    Seropian, Stuart
    Gross, Cary P.
    Huntington, Scott F.
    JNCI CANCER SPECTRUM, 2024, 8 (04)
  • [38] ASSESSMENT OF UTILITIES FOR ADVERSE EVENTS (AES) ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA (LBCL)
    Howell, T.
    Matza, L.
    Jun, M. P.
    Garcia, J.
    Powers, A.
    Maloney, D. G.
    VALUE IN HEALTH, 2020, 23 : S39 - S39
  • [39] Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
    Zhou, Lili
    Liu, Yifan
    Ye, Shiguang
    Li, Ping
    Li, Shaoguang
    Liang, Aibin
    BLOOD, 2023, 142
  • [40] CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma
    Gideon, Jacklyn
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (06) : 597 - 601
12345